Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients

Andrea Mariani, Sean Christopher Dowdy, William Arthur Cliby, Michael Haddock, Gary Keeney, Timothy G. Lesnick, Karl C. Podratz

Research output: Contribution to journalArticle

85 Citations (Scopus)

Abstract

Objective.: To assess the efficacy of systematic lymphadenectomy and adjuvant radiotherapy in minimizing pelvic sidewall and para-aortic failures. Methods.: Between January 1984 and December 2001, a total of 146 patients with stage III and IV endometrial cancer and lymph node metastases were treated at our institution. Adequate pelvic lymphadenectomy was defined as the removal of more than 10 pelvic lymph nodes, and adequate para-aortic lymphadenectomy was defined as removal of 5 or more para-aortic lymph nodes. The 24 patients who received adjuvant chemotherapy were excluded. We assessed the ability of adequate pelvic and para-aortic lymphadenectomy, together with radiotherapy, to prevent pelvic and para-aortic recurrences. Results.: Of the 122 patients studied, 94 (77%) had adequate pelvic lymphadenectomy and 47 (39%) had adequate para-aortic lymphadenectomy. Pelvic radiotherapy was administered to 78% and para-aortic radiotherapy to 29% of patients. Median follow-up of censored patients was 56 months. Twenty-five percent of patients had pelvic sidewall failure at 5 years. Pelvic sidewall failures at 5 years occurred in 57% of patients who had inadequate node dissection and/or no radiotherapy, compared with 10% for those having both adequate lymphadenectomy and radiotherapy (P < 0.001). After risk factor assessment in a regression model, only treatment with adequate lymphadenectomy and radiotherapy was a significant independent predictor of pelvic control (P = 0.03). The performance of definitive pelvic lymphadenectomy may have increased treatment-related morbidity in the subgroup of patients who had postoperative radiotherapy. For the 41 patients with positive para-aortic lymph nodes, the 5-year para-aortic failure rate was 34% after adequate lymphadenectomy but without adjuvant para-aortic radiotherapy. Likewise, 69% failed in the para-aortic area when adjuvant para-aortic radiotherapy was administered to patients not having adequate para-aortic lymphadenectomy; however, none of the 11 patients failed in the para-aortic area after adequate lymphadenectomy and para-aortic radiotherapy (P = 0.08). Conclusions.: Adequate (pelvic and para-aortic) lymphadenectomy and adjuvant radiotherapy appear complementary in reducing failures in both the pelvis and para-aortic areas in patients with node-positive endometrial cancer.

Original languageEnglish (US)
Pages (from-to)200-208
Number of pages9
JournalGynecologic Oncology
Volume101
Issue number2
DOIs
StatePublished - May 2006

Fingerprint

Adjuvant Radiotherapy
Endometrial Neoplasms
Lymph Node Excision
Radiotherapy
Lymph Nodes
Adjuvant Chemotherapy
Pelvis
Dissection

Keywords

  • Adjuvant radiotherapy
  • Endometrial cancer
  • Lymph node dissection
  • Lymphadenectomy
  • Metastasis
  • Para-aortic lymph nodes
  • Pelvic lymph nodes

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. / Mariani, Andrea; Dowdy, Sean Christopher; Cliby, William Arthur; Haddock, Michael; Keeney, Gary; Lesnick, Timothy G.; Podratz, Karl C.

In: Gynecologic Oncology, Vol. 101, No. 2, 05.2006, p. 200-208.

Research output: Contribution to journalArticle

@article{0408cf8913e348e284bf1407af953c10,
title = "Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients",
abstract = "Objective.: To assess the efficacy of systematic lymphadenectomy and adjuvant radiotherapy in minimizing pelvic sidewall and para-aortic failures. Methods.: Between January 1984 and December 2001, a total of 146 patients with stage III and IV endometrial cancer and lymph node metastases were treated at our institution. Adequate pelvic lymphadenectomy was defined as the removal of more than 10 pelvic lymph nodes, and adequate para-aortic lymphadenectomy was defined as removal of 5 or more para-aortic lymph nodes. The 24 patients who received adjuvant chemotherapy were excluded. We assessed the ability of adequate pelvic and para-aortic lymphadenectomy, together with radiotherapy, to prevent pelvic and para-aortic recurrences. Results.: Of the 122 patients studied, 94 (77{\%}) had adequate pelvic lymphadenectomy and 47 (39{\%}) had adequate para-aortic lymphadenectomy. Pelvic radiotherapy was administered to 78{\%} and para-aortic radiotherapy to 29{\%} of patients. Median follow-up of censored patients was 56 months. Twenty-five percent of patients had pelvic sidewall failure at 5 years. Pelvic sidewall failures at 5 years occurred in 57{\%} of patients who had inadequate node dissection and/or no radiotherapy, compared with 10{\%} for those having both adequate lymphadenectomy and radiotherapy (P < 0.001). After risk factor assessment in a regression model, only treatment with adequate lymphadenectomy and radiotherapy was a significant independent predictor of pelvic control (P = 0.03). The performance of definitive pelvic lymphadenectomy may have increased treatment-related morbidity in the subgroup of patients who had postoperative radiotherapy. For the 41 patients with positive para-aortic lymph nodes, the 5-year para-aortic failure rate was 34{\%} after adequate lymphadenectomy but without adjuvant para-aortic radiotherapy. Likewise, 69{\%} failed in the para-aortic area when adjuvant para-aortic radiotherapy was administered to patients not having adequate para-aortic lymphadenectomy; however, none of the 11 patients failed in the para-aortic area after adequate lymphadenectomy and para-aortic radiotherapy (P = 0.08). Conclusions.: Adequate (pelvic and para-aortic) lymphadenectomy and adjuvant radiotherapy appear complementary in reducing failures in both the pelvis and para-aortic areas in patients with node-positive endometrial cancer.",
keywords = "Adjuvant radiotherapy, Endometrial cancer, Lymph node dissection, Lymphadenectomy, Metastasis, Para-aortic lymph nodes, Pelvic lymph nodes",
author = "Andrea Mariani and Dowdy, {Sean Christopher} and Cliby, {William Arthur} and Michael Haddock and Gary Keeney and Lesnick, {Timothy G.} and Podratz, {Karl C.}",
year = "2006",
month = "5",
doi = "10.1016/j.ygyno.2006.01.032",
language = "English (US)",
volume = "101",
pages = "200--208",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients

AU - Mariani, Andrea

AU - Dowdy, Sean Christopher

AU - Cliby, William Arthur

AU - Haddock, Michael

AU - Keeney, Gary

AU - Lesnick, Timothy G.

AU - Podratz, Karl C.

PY - 2006/5

Y1 - 2006/5

N2 - Objective.: To assess the efficacy of systematic lymphadenectomy and adjuvant radiotherapy in minimizing pelvic sidewall and para-aortic failures. Methods.: Between January 1984 and December 2001, a total of 146 patients with stage III and IV endometrial cancer and lymph node metastases were treated at our institution. Adequate pelvic lymphadenectomy was defined as the removal of more than 10 pelvic lymph nodes, and adequate para-aortic lymphadenectomy was defined as removal of 5 or more para-aortic lymph nodes. The 24 patients who received adjuvant chemotherapy were excluded. We assessed the ability of adequate pelvic and para-aortic lymphadenectomy, together with radiotherapy, to prevent pelvic and para-aortic recurrences. Results.: Of the 122 patients studied, 94 (77%) had adequate pelvic lymphadenectomy and 47 (39%) had adequate para-aortic lymphadenectomy. Pelvic radiotherapy was administered to 78% and para-aortic radiotherapy to 29% of patients. Median follow-up of censored patients was 56 months. Twenty-five percent of patients had pelvic sidewall failure at 5 years. Pelvic sidewall failures at 5 years occurred in 57% of patients who had inadequate node dissection and/or no radiotherapy, compared with 10% for those having both adequate lymphadenectomy and radiotherapy (P < 0.001). After risk factor assessment in a regression model, only treatment with adequate lymphadenectomy and radiotherapy was a significant independent predictor of pelvic control (P = 0.03). The performance of definitive pelvic lymphadenectomy may have increased treatment-related morbidity in the subgroup of patients who had postoperative radiotherapy. For the 41 patients with positive para-aortic lymph nodes, the 5-year para-aortic failure rate was 34% after adequate lymphadenectomy but without adjuvant para-aortic radiotherapy. Likewise, 69% failed in the para-aortic area when adjuvant para-aortic radiotherapy was administered to patients not having adequate para-aortic lymphadenectomy; however, none of the 11 patients failed in the para-aortic area after adequate lymphadenectomy and para-aortic radiotherapy (P = 0.08). Conclusions.: Adequate (pelvic and para-aortic) lymphadenectomy and adjuvant radiotherapy appear complementary in reducing failures in both the pelvis and para-aortic areas in patients with node-positive endometrial cancer.

AB - Objective.: To assess the efficacy of systematic lymphadenectomy and adjuvant radiotherapy in minimizing pelvic sidewall and para-aortic failures. Methods.: Between January 1984 and December 2001, a total of 146 patients with stage III and IV endometrial cancer and lymph node metastases were treated at our institution. Adequate pelvic lymphadenectomy was defined as the removal of more than 10 pelvic lymph nodes, and adequate para-aortic lymphadenectomy was defined as removal of 5 or more para-aortic lymph nodes. The 24 patients who received adjuvant chemotherapy were excluded. We assessed the ability of adequate pelvic and para-aortic lymphadenectomy, together with radiotherapy, to prevent pelvic and para-aortic recurrences. Results.: Of the 122 patients studied, 94 (77%) had adequate pelvic lymphadenectomy and 47 (39%) had adequate para-aortic lymphadenectomy. Pelvic radiotherapy was administered to 78% and para-aortic radiotherapy to 29% of patients. Median follow-up of censored patients was 56 months. Twenty-five percent of patients had pelvic sidewall failure at 5 years. Pelvic sidewall failures at 5 years occurred in 57% of patients who had inadequate node dissection and/or no radiotherapy, compared with 10% for those having both adequate lymphadenectomy and radiotherapy (P < 0.001). After risk factor assessment in a regression model, only treatment with adequate lymphadenectomy and radiotherapy was a significant independent predictor of pelvic control (P = 0.03). The performance of definitive pelvic lymphadenectomy may have increased treatment-related morbidity in the subgroup of patients who had postoperative radiotherapy. For the 41 patients with positive para-aortic lymph nodes, the 5-year para-aortic failure rate was 34% after adequate lymphadenectomy but without adjuvant para-aortic radiotherapy. Likewise, 69% failed in the para-aortic area when adjuvant para-aortic radiotherapy was administered to patients not having adequate para-aortic lymphadenectomy; however, none of the 11 patients failed in the para-aortic area after adequate lymphadenectomy and para-aortic radiotherapy (P = 0.08). Conclusions.: Adequate (pelvic and para-aortic) lymphadenectomy and adjuvant radiotherapy appear complementary in reducing failures in both the pelvis and para-aortic areas in patients with node-positive endometrial cancer.

KW - Adjuvant radiotherapy

KW - Endometrial cancer

KW - Lymph node dissection

KW - Lymphadenectomy

KW - Metastasis

KW - Para-aortic lymph nodes

KW - Pelvic lymph nodes

UR - http://www.scopus.com/inward/record.url?scp=33646392731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646392731&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2006.01.032

DO - 10.1016/j.ygyno.2006.01.032

M3 - Article

C2 - 16510174

AN - SCOPUS:33646392731

VL - 101

SP - 200

EP - 208

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -